NCT03066427View on ClinicalTrials.gov

Study to Evaluate Efficacy and Safety of Sunitinib in Renal Cell Carcinoma Progressed to 1L Immunotherapy Treatment.

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

May 10, 2017

Primary Completion Date

September 22, 2020

Study Completion Date

September 22, 2020

Conditions
Clear Cell Renal Carcinoma
Interventions
DRUG

Sunitinib

Sunitinib 50 mg/d

Trial Locations (9)

14004

Complejo Hospitalario Regional Reina Sofía, Córdoba

28034

Hospital Ramón Y Cajal, Madrid

28041

Hospital Universitario 12 de Octubre, Madrid

08908

ICO Duran i Reynals, L'Hospitalet de Llobregat

08035

Hospital Universitari Vall d'Hebron, Barcelona

08036

Hospital Clínic i Provincial de Barcelona, Barcelona

Unknown

Centro Integral Oncologico Clara Campal, Madrid

MD Anderson Cancer Center Madrid, Madrid

Hospital Central de Asturias, Oviedo

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

collaborator

Apices Soluciones S.L.

INDUSTRY

lead

Spanish Oncology Genito-Urinary Group

OTHER

NCT03066427 - Study to Evaluate Efficacy and Safety of Sunitinib in Renal Cell Carcinoma Progressed to 1L Immunotherapy Treatment. | Biotech Hunter | Biotech Hunter